Part I: Clinical Protocol and Data Management. The UCDCCC Office of Clinical Research (OCR), formerly the Clinical Trials Support Unit, is led by Associate Director for Clinical Research (Karen Kelly, MD) and OCR Executive Director (Cinda Lyon, RN). The OCR includes five units: operations, business, regulatory, phase I and clinical, thus providing cancer center investigators with a centralized resource providing a full repertoire of services to conduct clinical trials. The OCR staff work cohesively with the Investigators to provide subjects with exceptional care such that toxicities are minimized, trial adherence is maintained and data quality is achieved. Part II: Data and Safety Monitoring. All clinical trials conducted under the auspices of UCDCCC include provisions for data and safety monitoring. The Data Safety and Monitoring Plan (DSMP) focuses on patient safety, protocol adherence and quality of data. It was recently revised to provide oversight of clinical trial conduct in accordance with NCI guidelines. Part III: Inclusion of Minorities and Women in Clinical Trials. The UCDCCC is dedicated to the inclusion of women and minorities in our cancer clinical trials and complies with the NIH regulations on accrual of these populations. Entry criteria for cancer studies are disease, not gender or ethnicity specific. The sex/gender and racial/ethnic makeup of the study population for any one trial will be influenced by the frequency of the diagnosis in various subgroups. We offer clinical trials focused on cancers for which minority populations experience disparities, for example, liver cancer (Asian Americans and all populations of color), prostate cancer (African Americans and Hispanics), and breast cancer (African Americans, Hispanics, and Asian Americans). Although protocols are open to women who meet the eligibility criteria, pregnant and nursing women are excluded because of unknown risks of anti-neoplastic agents to fetuses and infants. Part IV: Inclusion of Children in Clinical Trials. UCDCCC, through the Pediatric Oncology Division, offers a large variety of clinical cancer research trials to the children of Sacramento and the surrounding area. These trials address a wide variety of pediatric malignancies, including (but not limited to) leukemia/lymphoma, osteosarcoma, Wilms Tumor and neuroblastoma.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA093373-14
Application #
9148406
Study Section
Subcommittee A - Cancer Centers (NCI-A)
Project Start
Project End
Budget Start
2016-07-01
Budget End
2017-06-30
Support Year
14
Fiscal Year
2016
Total Cost
$282,197
Indirect Cost
$102,454
Name
University of California Davis
Department
Type
DUNS #
047120084
City
Davis
State
CA
Country
United States
Zip Code
95618
York, D; Sproul, C D; Chikere, N et al. (2018) Expression and targeting of transcription factor ATF5 in dog gliomas. Vet Comp Oncol 16:102-107
Wang, Minan; Yao, Li-Chin; Cheng, Mingshan et al. (2018) Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy. FASEB J 32:1537-1549
Wang, Fuli; Zhang, Hongyong; Ma, Ai-Hong et al. (2018) COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin. Mol Cancer Ther 17:474-483
Fletcher, Kyle; Klosterman, Steven J; Derevnina, Lida et al. (2018) Comparative genomics of downy mildews reveals potential adaptations to biotrophy. BMC Genomics 19:851
Yuan, Ye; He, Yixuan; Bo, Ruonan et al. (2018) A facile approach to fabricate self-assembled magnetic nanotheranostics for drug delivery and imaging. Nanoscale 10:21634-21639
Seo, Jai Woong; Tavaré, Richard; Mahakian, Lisa M et al. (2018) CD8+ T-Cell Density Imaging with 64Cu-Labeled Cys-Diabody Informs Immunotherapy Protocols. Clin Cancer Res 24:4976-4987
Xue, Xiangdong; Huang, Yee; Bo, Ruonan et al. (2018) Trojan Horse nanotheranostics with dual transformability and multifunctionality for highly effective cancer treatment. Nat Commun 9:3653
Knight, Jennifer F; Sung, Vanessa Y C; Kuzmin, Elena et al. (2018) KIBRA (WWC1) Is a Metastasis Suppressor Gene Affected by Chromosome 5q Loss in Triple-Negative Breast Cancer. Cell Rep 22:3191-3205
Couto, K M; Moore, P F; Zwingenberger, A L et al. (2018) Clinical characteristics and outcome in dogs with small cell T-cell intestinal lymphoma. Vet Comp Oncol 16:337-343
Dou, John; Schmidt, Rebecca J; Benke, Kelly S et al. (2018) Cord blood buffy coat DNA methylation is comparable to whole cord blood methylation. Epigenetics 13:108-116

Showing the most recent 10 out of 836 publications